ID   JHH-5
AC   CVCL_0364
AS   CVCL_0263
SY   Jhh-5; JHH5; FLC-5; FLC5; Functional Liver Cell-5
DR   EFO; EFO_0006602
DR   MCCL; MCC:0000154
DR   MCCL; MCC:0000258
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioGRID_ORCS_Cell_line; 633
DR   BioSample; SAMN03473192
DR   BioSample; SAMN10987783
DR   cancercelllines; CVCL_0364
DR   Cell_Model_Passport; SIDM01569
DR   Cosmic; 2023875
DR   DepMap; ACH-000734
DR   EGA; EGAS00001000610
DR   GEO; GSM887172
DR   GEO; GSM888244
DR   GEO; GSM936767
DR   GEO; GSM2551574
DR   IARC_TP53; 28347
DR   JCRB; JCRB1029
DR   JCRB; NIHS0279
DR   LiGeA; CCLE_881
DR   LIMORE; JHH5
DR   PharmacoDB; JHH5_683_2019
DR   Progenetix; CVCL_0364
DR   Wikidata; Q54898642
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=1701409;
RX   PubMed=8835345;
RX   PubMed=9359923;
RX   PubMed=10523694;
RX   PubMed=10933057;
RX   PubMed=17241388;
RX   PubMed=22460905;
RX   PubMed=23505090;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31063779;
RX   PubMed=31068700;
RX   PubMed=31378681;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=36724073;
WW   https://lccl.zucmanlab.com/hcc/cellLines/JHH5
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Japanese.
CC   Doubling time: 30.39 hours (PubMed=31378681); ~40 hours (Note=Lot 03112003), ~2 days (Note=Lot 03022011), ~29 hours (Note=Lot 09272018), ~1 day (Note=Lot 08252021) (JCRB=JCRB1029).
CC   HLA typing: A*24:02,24:02; B*08:01,67:02; C*01:02,12:02; DQA1*01:02,01:02; DQB1*03:02,03:02; DRB1*11:12,15:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Gln6Argfs*22 (c.17_18delAG); Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700; PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190_His193del (c.569_580del12); Zygosity=Unspecified (DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.41%; Native American=0.04%; East Asian, North=81.84%; East Asian, South=17.72%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0279; true.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): JCRB; PubMed=25877200; PubMed=31378681
ST   Amelogenin: X,Y
ST   CSF1PO: 9
ST   D13S317: 9
ST   D16S539: 9,10
ST   D18S51: 13
ST   D21S11: 31.2
ST   D3S1358: 15,17
ST   D5S818: 13
ST   D7S820: 10,12
ST   D8S1179: 12
ST   FGA: 19
ST   Penta D: 11
ST   Penta E: 17,20
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 17,19
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 33
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=1701409;
RA   Fujise K., Nagamori S., Hasumura S., Homma S., Sujino H., Matsuura T.,
RA   Shimizu K., Niiya M., Kameda H., Fujita K., Ohno T.;
RT   "Integration of hepatitis B virus DNA into cells of six established
RT   human hepatocellular carcinoma cell lines.";
RL   Hepato-Gastroenterol. 37:457-460(1990).
//
RX   PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A;
RA   Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K.,
RA   Kosaka T., Tsuji T., Namba M.;
RT   "Persistence of hepatitis C virus RNA in established human
RT   hepatocellular carcinoma cell lines.";
RL   J. Med. Virol. 48:133-140(1996).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-i., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=10523694; DOI=10.3892/or.6.6.1267;
RA   Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.;
RT   "Yeast functional assay of the p53 gene status in 11 cell lines and 26
RT   surgical specimens of human hepatocellular carcinoma.";
RL   Oncol. Rep. 6:1267-1271(1999).
//
RX   PubMed=10933057; DOI=10.1038/sj.neo.7900046;
RA   Murakami K., Sakukawa R., Ikeda T., Matsuura T., Hasumura S.,
RA   Nagamori S., Yamada Y., Saiki I.;
RT   "Invasiveness of hepatocellular carcinoma cell lines: contribution of
RT   membrane-type 1 matrix metalloproteinase.";
RL   Neoplasia 1:424-430(1999).
//
RX   PubMed=17241388; DOI=10.1111/j.1478-3231.2006.01410.x;
RA   Kosuge M., Takizawa H., Maehashi H., Matsuura T., Matsufuji S.;
RT   "A comprehensive gene expression analysis of human hepatocellular
RT   carcinoma cell lines as components of a bioartificial liver using a
RT   radial flow bioreactor.";
RL   Liver Int. 27:101-108(2007).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z.,
RA   Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K.,
RA   Xu J.-C.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=36724073; DOI=10.1016/j.celrep.2023.112065;
RA   Yang J.-C., Guo F.-S., Chin H.-S., Chen G.-B., Ang C.-H., Lin Q.-S.,
RA   Hong W.-J., Fu N.-Y.;
RT   "Sequential genome-wide CRISPR-Cas9 screens identify genes regulating
RT   cell-surface expression of tetraspanins.";
RL   Cell Rep. 42:112065.1-112065.26(2023).
//